/XFOR
XFOR Stock - X4 Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$3.60-1.64%
$0.06 (-1.64%) • Dec 19
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.41
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+143.1%upside
Target: $8.75
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for XFOR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.56 – $3.64
TARGET (TP)$8.75
STOP LOSS$3.31
RISK/REWARD1:17.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.42
52W High$26.82
52W Low$1.35
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.56M | N/A | N/A | N/A | $3.00M |
| Gross Profit | $1.76M | N/A | N/A | N/A | $3.00M |
| Gross Margin | 68.8% | N/A | N/A | N/A | 100.0% |
| Operating Income | $-36,401,000 | $-107,522,000 | $-87,569,000 | $-85,107,000 | $-59,874,000 |
| Net Income | $-37,450,000 | $-101,167,000 | $-93,867,000 | $-88,696,000 | $-62,131,000 |
| Net Margin | -1464.6% | N/A | N/A | N/A | -2071.0% |
| EPS | $-5.59 | $-17.10 | $-45.60 | $-119.70 | $-92.70 |
Company Overview
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
67%
Hold / Neutral
1
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish1 Neutral/Bearish
Price Targets
$4
Average Target
↑ 11.1% Upside
Now
$1
Low
$4
Average
$10
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 5th 2025 | Stifel | Resumed | Buy | $10 |
| December 12th 2023 | B. Riley Securities | Downgrade | Neutral | $1← $3 |
| August 30th 2023 | B. Riley Securities | Resumed | Buy | $3 |
| December 22nd 2022 | Cantor Fitzgerald | Initiation | Overweight | $3 |
| December 12th 2022 | Piper Sandler | Initiation | Overweight | $3 |
Earnings History & Surprises
XFORBeat Rate
42%
Last 19 quarters
Avg Surprise
-4.7%
EPS vs Estimate
Beats / Misses
8/11
Last 12 quarters
Latest EPS
$-0.69
Q4 2025
EPS Surprise History
Q1 24
+33.3%
$-0.10vs$-0.15
Q2 24
-52.9%
$-0.26vs$-0.17
Q3 24
-40.0%
$-0.07vs$-0.05
Q4 24
-5.9%
$-0.18vs$-0.17
Q1 25
-17.6%
$-6.01vs$-5.11
Q2 25
+101.0%
$0.04vs$-4.13
Q3 25
+23.4%
$-3.47vs$-4.53
Q4 25
+12.7%
$-0.69vs$-0.79
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 24, 2026 | $-0.34 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.79 | $-0.69 | +12.7% | ✓ BEAT |
Q3 2025 | Aug 8, 2025 | $-4.53 | $-3.47 | +23.4% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-4.13 | $0.04 | +101.0% | ✓ BEAT |
Q1 2025 | Mar 25, 2025 | $-5.11 | $-6.01 | -17.6% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.17 | $-0.18 | -5.9% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.05 | $-0.07 | -40.0% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.17 | $-0.26 | -52.9% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-0.15 | $-0.10 | +33.3% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.15 | $-0.01 | +93.3% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.17 | $-0.33 | -94.1% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.20 | $-0.16 | +20.0% | ✓ BEAT |
Q1 2023 | Mar 21, 2023 | $-0.23 | $-0.29 | -26.1% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.31 | $-0.26 | +16.1% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.65 | $-0.60 | +7.7% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.62 | $-0.72 | -16.1% | ✗ MISS |
Q1 2022 | Mar 17, 2022 | $-0.68 | $-1.24 | -82.4% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.72 | $-0.76 | -5.6% | ✗ MISS |
Q3 2021 | Aug 3, 2021 | $-0.73 | $-0.74 | -1.4% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-0.84 | $-1.30 | -54.8% | ✗ MISS |
Latest News
Stifel Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $10
📈 PositiveBenzinga•Dec 5, 2025, 05:29 PM•Also:
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5
📈 PositiveBenzinga•Nov 10, 2025, 12:09 PM
X4 Pharmaceuticals Q3 EPS $(0.69) Beats $(0.82) Estimate, Sales $1.765M Miss $1.901M Estimate
➖ NeutralBenzinga•Nov 5, 2025, 01:22 PM
X4 Pharmaceuticals shares are trading higher. The company priced $135 million public offering of 45.86 million common shares at $2.90 each to advance phase 3 rare disease program.
📈 PositiveBenzinga•Oct 24, 2025, 05:59 PM
X4 Pharmaceuticals drops 5%, prices $135M equity
📉 NegativeSeeking Alpha•Oct 24, 2025, 06:52 AM
X4 Pharmaceuticals Prices $135M Public Offering Of 45.86M Common Shares At $2.90 Each To Advance Phase 3 Rare Disease Program
➖ NeutralBenzinga•Oct 24, 2025, 06:25 AM
X4 Pharmaceuticals Launches Of An Underwritten Public Offering Of Its Common Stock; No Financial Terms Disclosed
➖ NeutralBenzinga•Oct 23, 2025, 08:05 PM
X4 Pharmaceuticals Announces Strategic Restructuring With 50% Workforce Reduction Expected To Deliver $13M Annualized Cost Savings
➖ NeutralBenzinga•Sep 17, 2025, 11:12 AM
Stifel Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $9
➖ NeutralBenzinga•Aug 29, 2025, 01:13 PM•Also:
X4 Pharmaceuticals secures $60M PIPE financing
📈 PositiveSeeking Alpha•Aug 12, 2025, 01:49 PM
X4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropenia
📈 PositiveSeeking Alpha•Jun 10, 2025, 12:12 PM
Frequently Asked Questions about XFOR
What is XFOR's current stock price?
X4 Pharmaceuticals, Inc. (XFOR) is currently trading at $3.60 per share. The stock has moved -1.64% today.
What is the analyst price target for XFOR?
The average analyst price target for XFOR is $8.75, based on 1 analyst.
What sector is X4 Pharmaceuticals, Inc. in?
X4 Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is XFOR's market cap?
X4 Pharmaceuticals, Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does XFOR pay dividends?
No, X4 Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALGS
Aligos Therapeutics, Inc.
$10.68
Mkt Cap: $0.1B
FGEN
FibroGen, Inc.
$8.60
Mkt Cap: $0.0B
INMB
INmune Bio, Inc.
$1.83
Mkt Cap: $0.0B
KPTI
Karyopharm Therapeutics Inc.
$6.94
Mkt Cap: $0.1B
KZR
Kezar Life Sciences, Inc.
$6.34
Mkt Cap: $0.0B
MRSN
Mersana Therapeutics, Inc.
$28.94
Mkt Cap: $0.1B
OKUR
OnKure Therapeutics, Inc.
$3.01
Mkt Cap: $0.0B
SKYE
Skye Bioscience, Inc.
$0.93
Mkt Cap: $0.0B
SNTI
Senti Biosciences, Inc.
$1.20
Mkt Cap: $0.0B
TPST
Tempest Therapeutics, Inc.
$3.12
Mkt Cap: $0.0B
Explore stocks similar to XFOR for comparison